Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

GlaxoSmithKline PLC (NYSE:GSK)

40.76
Delayed Data
As of 4:02pm ET
 -0.22 / -0.54%
Today’s Change
37.24
Today|||52-Week Range
49.08
+1.02%
Year-to-Date
4 Can't-Miss Numbers From GlaxoSmithKline's Fourth-Quarter Results
Feb 04 / MotleyFool.com
Novice Trade: GlaxoSmithKline
Feb 01 / TheStreet.com
Is Inovio Pharmaceuticals' Zika Surge Premature?
Feb 04 / MotleyFool.com
Rally Hobbled As Ugly China Reality Replaces Japan NIRP Euphoria; Oil Rebound Fizzles
Feb 01 / Investing Channel
Glaxo Tops Q4 Earnings, Revenues Rise Y/Y, 2016 View Intact
Feb 04 / Zacks.com
3 Feverishly Bad Flu Myths That Should Be Put to Rest
Jan 31 / MotleyFool.com
Frontrunning: February 4
Feb 04 / Investing Channel
The 3 Most Important Numbers When GlaxoSmithKline Reports Its Fourth-Quarter Results
Jan 29 / MotleyFool.com
GlaxoSmithKline (GSK) Earnings Report: Q4 2015 Conference Call Transcript
Feb 04 / TheStreet.com
CDXS and LOGI are Aggressive Growth Stocks
Jan 28 / Zacks.com
3 Value Stocks Near 52-Week Lows Worth Buying
Feb 04 / MotleyFool.com
Novartis (NVS) Lags Q4 Earnings & Revenues, Alcon Down
Jan 28 / Zacks.com
3 Stocks Driving The Drugs Industry Higher
Feb 03 / TheStreet.com
Is Another Big Transformation on the Way for GlaxoSmithKline?
Jan 28 / MotleyFool.com
3 Hold-Rated Dividend Stocks: QCOM, MDC, GSK
Feb 03 / TheStreet.com
OncoMed Tanks on Phase II Pancreatic Cancer Study Update
Jan 27 / Zacks.com
Glaxo (GSK) Beats on Q4 Earnings, Revenues Rise Y/Y
Feb 03 / Zacks.com
Novartis (NVS) Posts Lower-Than-Expected Earnings in Q4
Jan 27 / Zacks.com
GlaxoSmithKline (GSK) Strong In Pre-Market Trading
Feb 03 / TheStreet.com
Forget Pfizer Inc.: Here Are 2 Better Dividend Stocks
Jan 26 / MotleyFool.com
Why Axovant Sciences Shares Are Crashing
Feb 02 / MotleyFool.com
Why OncoMed Pharmaceuticals' Stock Crashed Today
Jan 25 / MotleyFool.com
Can GlaxoSmithKline (GSK) Q4 Earnings Surprise Estimates?
Feb 01 / Zacks.com
Investors are terrified ... and they're overreacting
Jan 15 / CNNMoney.com